Media headlines about Endo International PLC (NASDAQ:ENDP) have been trending somewhat positive this week, AlphaOne Sentiment reports. AlphaOne, a service of Accern, scores the sentiment of media coverage by analyzing more than twenty million blog and news sources in real time. AlphaOne ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Endo International PLC earned a media sentiment score of 0.15 on AlphaOne’s scale. AlphaOne also gave news articles about the company an impact score of 62 out of 100, meaning that recent media coverage is somewhat likely to have an effect on the company’s share price in the next few days.
Here are some of the media stories that may have impacted Alpha One Sentiment Analysis’s rankings:
- Endo International plc (NASDAQ:ENDP) Sees Volume Pop in Session (fumbleboard.com)
- Insider Activity of Endo International plc (ENDP) (latribunadecanarias.com)
- Endo International PLC (ENDP) PT Set at $12.00 by Canaccord Genuity (thewestcoastsportsblog.com)
- Cantor’s First Take: Bullish on Valeant Pharmaceuticals Intl Inc (VRX), Sidelined on Endo International (ENDP) (finance.yahoo.com)
- Is Endo International (ENDP) a Great Stock for Value Investors? (finance.yahoo.com)
Endo International PLC (NASDAQ:ENDP) traded down 0.28% during trading on Friday, hitting $10.77. 6,198,008 shares of the stock traded hands. Endo International PLC has a one year low of $9.70 and a one year high of $24.93. The stock’s market cap is $2.40 billion. The company has a 50-day moving average price of $12.25 and a 200 day moving average price of $12.75.
Endo International PLC (NASDAQ:ENDP) last released its quarterly earnings data on Tuesday, May 9th. The company reported $1.23 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.10 by $0.13. Endo International PLC had a positive return on equity of 25.32% and a negative net margin of 82.93%. The business had revenue of $1.04 billion for the quarter, compared to analysts’ expectations of $1.02 billion. During the same quarter in the previous year, the business posted $1.08 EPS. Endo International PLC’s revenue for the quarter was up 7.7% on a year-over-year basis. Analysts expect that Endo International PLC will post $3.58 earnings per share for the current year.
A number of research firms recently issued reports on ENDP. William Blair restated a “market perform” rating on shares of Endo International PLC in a report on Wednesday. Royal Bank of Canada set a $15.00 target price on shares of Endo International PLC and gave the company a “hold” rating in a report on Monday. BidaskClub downgraded shares of Endo International PLC from a “hold” rating to a “sell” rating in a research note on Thursday. Cantor Fitzgerald started coverage on shares of Endo International PLC in a research note on Friday. They set a “neutral” rating and a $12.00 price objective for the company. Finally, Canaccord Genuity set a $12.00 price objective on shares of Endo International PLC and gave the stock a “hold” rating in a research note on Thursday, June 8th. Two research analysts have rated the stock with a sell rating, fifteen have assigned a hold rating and six have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average target price of $18.74.
COPYRIGHT VIOLATION WARNING: This article was posted by Chaffey Breeze and is the property of of Chaffey Breeze. If you are reading this article on another domain, it was stolen and republished in violation of U.S. & international copyright and trademark laws. The original version of this article can be accessed at https://www.chaffeybreeze.com/2017/06/16/endo-international-plc-endp-receives-media-impact-score-of-0-15-updated.html.
About Endo International PLC
Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.
Receive News & Ratings for Endo International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International PLC and related companies with MarketBeat.com's FREE daily email newsletter.